Research from Northwestern University revealed that fragments of Borrelia burgdorferi bacterial cell walls persist in the liver, disrupting protein expression and elevating liver dysfunction biomarkers in post-treatment Lyme disease syndrome (PTLDS) patients. This novel evidence ties bacterial peptidoglycan presence to systemic pathology, moving the field closer to clarifying PTLDS mechanisms and potentially guiding effective treatments.